Benzinga's Small Cap Movers for Friday February 1, 2013
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
Shares of EDAP (NASDAQ: EDAP), the Lyon, France provider of therapeutic ultrasound, rose almost 18% Friday on 10 times average volume.
EDAP announced Friday the submission of its Pre-Market Approval application to the U.S. Food and Drug Administration on January 31, 2013 for the Company's Ablatherm-HIFU for treatment of low risk, localized prostate cancer. EDAP's PMA submission includes data from the ENLIGHT study, a multi-center U.S. Phase II/III clinical trial that completed the two year follow-up needed to evaluate its primary endpoint in August 2012, as well as data from the Company's extensive worldwide database of treatment information and follow-up data from patients who have undergone HIFU therapy for prostate cancer.
EDAP closed at $3.04 on Friday.
Kandi Technologies (NASDAQ: KNDI), the China-based producer of electric vehicles, rose 11% Friday on 3 times average volume.
Kandi Technologies and Geely Automotive (OTC: GELYF) entered into a joint venture agreement to engage in the investment, research and development, production, marketing and sales of electric vehicles in China.
Kandi Technologies closed at $4.01 on Friday.
Concurrent Computer Corp
Shares of Concurrent Computer Corp (NASDAQ: CCUR), the Atlanta, GA provider of video, media data intelligence and real-time Linux solutions, rose 14% Friday on 18 times average volume.
Concurrent Computer was the subject of an email promotion on Friday.
Concurrent Computer closed at $7.49 on Friday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.